P&G Intrinsa Gets No Satisfaction; Potential Risks Outweigh Sexual Benefits

FDA’s Reproductive Health Drugs Advisory Committee votes unanimously Dec. 2 that current efficacy and safety data for the female sexual dysfunction therapy do not support approval. Committee recommends completion of safety studies in pre- and postmenopausal women prior to approval.